| Azobenzene-containing conjugated polymers-camptothecin-chlorin e6 NPs (CPs-CPT-Ce6) |
Chlorin e6 (Ce6) |
Camptothecin (CPT) |
HeLa |
In vitro, Animals |
The –N=N– functional groups in azobenzene could be reduced and cleaved by AZO reductase in tumor hypoxia, promoting ROS production. Controlled release of CPT through the reduction of CPs by AZO reductase.
|
[92] 2018 |
| Cyclic pentapeptide cRGDfk and Chlorin e6 conjugated silk fibroin (SF)-based NPs |
Chlorin e6 (Ce6) |
5-Fluorouracil (5-FU) |
MGC-803 |
In vitro, Animals |
cRGDfk specifically targets and binds overexpressed αvβ3 integrin receptors on MGC-803 cells to increase tumor aggregation of the drug. Induced high reactive oxygen species generation and produced a good antitumor effect.
|
[93] 2018 |
| DOX- and perfluorocarbon (PFC)- loaded fluorinated aza-boron-dipyrromethene (PDNBF) NPs |
Fluorinated aza-boron-dipyrromethene (NBF) |
DOX |
4T1 |
In vitro, Animals |
High doxorubicin loading efficiency (25%). PDNBF NPs could be effectively enriched at the tumor site, and DOX could be explosively released by laser irradiation. Significantly inhibited tumor growth and mediated in vivo ultrasound and photoacoustic imaging.
|
[94] 2020 |
| Pluronic F127 encapsulated halogenated boron-dipyrromethene NPs (LBBr2 NPs and LBCl2 NPs) |
Halogenated boron-dipyrromethene (BDPBr2 and BDPCl2) |
Lenvatinib |
Hep3B, Huh7 |
In vitro |
Improved the water solubility of drugs Controlled release through pH response and enhanced the targeting of chemotherapy drugs. Significantly inhibited tumor growth by chemotherapy/photodynamic cotherapy.
|
[95] 2021 |
| Lactobionic acid-catalase-cis-aconitic anhydride-linked doxorubicin @ chlorin e6 (LA-CAT-CAD@Ce6) |
Chlorin e6 (Ce6) |
cis-Aconitic anhydride-linked doxorubicin
(DOX precursor) |
EMT6 |
In vitro, Animals |
Lactobionic acid acted as an active targeting ligand to increase cellular internalization. Controlled release through pH response. Decreased the expression of hypoxia-inducible factor-1α and improved the therapeutic effect.
|
[96] 2020 |
| Pyropheophorbide a–polyethylene glycol 2000 (Ppa-PEG2k) |
Pyropheophorbide a (Ppa) |
ROS-responsive oleate prodrug of paclitaxel (PTX) |
A549, 4T1 |
In vitro, Animals |
|
[97] 2019 |
| Poly (oligo (ethylene glycol) methacrylate)-Paclitaxel @Chlorin e6 NPs |
Chlorin e6 (Ce6) |
B-sensitive polymer-paclitaxel (PTX) |
T24 |
In vitro, Animals |
Photointernalization (PCI) accelerated the uptake of NPs by tumor cells. Tumor growth was significantly inhibited in a PDX model, and the inhibition rate was more than 98%.
|
[98] 2021 |
| Polyethylene glycol-peptide-poly(ω-pentadecalactone-co-N-methyldiethyleneamine-co-3,3′-thiodipropionate) (PEG-M-PPMT) nanoparticles (NPs) |
Chlorin e6 (Ce6) |
Sorafenib (SRF) |
A549 |
In vitro, Animals |
Increased serum stability of Ce6 and SRF and enhanced drug aggregation in tumors by EPR. Overexpressed MMP-2 in tumor extracellular matrix could partially shed PEG from NPs and form smaller particles that penetrate into tumor tissue. Acidic pH and high intracellular ROS levels accelerated drug release and rapidly killed tumor cells.
|
[99] 2020 |
| (Phenylboronic acid4-E2E)2-Protoporphyrin IX-(Lipoic acid)2
|
Protoporphyrin IX (PpIX) |
Paclitaxel (PTX) |
A549 |
In vitro, Animals |
PTX blocks mitosis and makes cells stay at G2/M, prolonging the destruction time of nuclear membrane and promoting the accumulation of photosensitizer in the nucleus. PDT enhanced the internalization and release rate of PTX by destroying lysosomes.
|
[100] 2020 |
| Poly(ethylene glycol)-b-PMPMC-g-paclitaxel-g-PyTPE micelles (PMPT) |
PyTPE, TB |
Paclitaxel-SS-N3
(PTX-SS-N3) |
HeLa |
In vitro, Animals |
Increased uptake of drugs by cells through photochemical internalization (PCI). The high expression of intracellular glutathione was used to break disulfide bonds and induce the release and aggregation of PTX to induce the change in aggregation state of luminescence.
|
[101] 2021 |
